Insulin-like growth factor
binding protein-3 (IGFBP-3), a secretory protein, is the most abundant IGF
binding protein present in human serum among all IGF binding proteins. IGFBP-3
shows decreased level of expression in cancerous cells but has been known to be
present in significant amounts in normal or non-cancerous cells. IGFBP-3 can
induce apoptosis in prostate cancer cells either in an IGF-dependent manner or
independently of IGF binding. Although putative cell death specific
Insulin-like growth factor binding protein-3 (IGFBP-3R) receptor(s) has
recently been identified by which IGFBP-3 may induce its anti-tumor effects,
IGFBP-3 has also been known to activate various downstream intracellular
signaling molecules via a different mechanistic pathway. Stat-1 has been known
to be one of the candidate molecules activated by IGFBP-3. IGFBP-3 can also
inhibit Akt/IGF-1 survival pathway in MCF-7 breast cancer cells which
ultimately leads to the induction of apoptosis in these cells. All these
studies clearly demonstrate that IGFBP-3 regulates cell proliferation and
promotes its pro-apoptotic effects in cancer cells in two different pathways:
1) sequester IGF-I to bind to IGF-I receptor to inhibit cell proliferation and
induce apoptosis, 2) independent of IGF-I pathway, IGFBP-3 binds to some
putative receptor and activate various downstream pro-apoptotic molecules
involved in cell death.
Apoptosis IGFBP-3 Stat-1 IGF-I TGF-<i>β</i>1. IGFBP-3 Expression and Function
Insulin-like growth factor binding protein-3 (IGFBP-3) is one of the six known IGF binding proteins present in human serum and is comprised of 264-amino acid mature protein, with a 27-amino acid signal peptide [1] . IGFBP-3 is expressed in a wide variety of tissues. Epidemiological studies have clearly suggested that there is an inverse relationship between IGFBP-3 levels and occurrence of cancers [2] . Increased expression levels of serum IGFBP-3 result in decreased prevalence of prostate [3] [4] and colorectal [5] [6] cancers. It has also been shown that IGFBP-3 over expression results in decreased tumor formation in xenografts of non-small lung cancer cells [7] and M12 human prostate cancer cells [8] . Patient samples with hepatocellular and non-small cell lung carcinoma have been shown to have decreased expression of IGFBP-3 [9] [10] . Besides, it has also been reported that there is an increased level of IGFBP-3 in senescence [11] . In addition, IGFBP-3 expression level was decreased in cells immortalized with the human papillomavirus type 16 oncoprotein E7 due to proteasomal degradation [12] . Although IGFBP-3 is a secretory protein, but active protein could also be found in nucleus and cytoplasm [13] . Besides its full length form, IGFBP-3 could also be found in an N-terminal truncated form [14] [15] .
IGFBP-3 has been known to play an important role in cell proliferation by inducing its anti-proliferative and pro-apoptotic effects in breast and prostate cancer cells [16] -[18] . It has also been shown that IGFBP-3 not only triggers growth inhibitory effects by inducing apoptosis, but also can function in G1 cell cycle arrest in human breast, kidney and lung cancer cells [19] [20] . IGFBP-3 may also play an important role in mediating inhibitory effects of transforming growth factor (TGF)-β (Figure 1), retinoic acid, tumor necrosis factor (TNF)-α and p53 [16] [21] -[26] , but modulation in IGFBP-3 synthesis or action could regulate these anti-proliferative effects.
2. IGF-Dependent and Independent Effect of IGFBP-3
IGF dependent studies revealed that Insulin-like growth factor binding protein (IGFBP)-3 could induce apoptosis by binding to IGF-I and form a binary complex with IGF-I and prevent it to activate (IGF-IR) IGF-1 receptor (Figure 2) to stimulate cell proliferation and survival [27] [28] . In addition, Insulin-like growth factor binding protein (IGFBP)-3 has been shown to potently inhibit cell proliferation and induce apoptosis in an insulin-like growth factor (IGF)-independent manner [13] [18] [29] . IGFBP-3 in the media may exert its pro-apoptotic effects by binding to some cell surface receptors resulting in the activation of various signal transduction pathways.
Key candidate molecules activated by IGFBP-3. IGFBP-3 can activate various downstream signaling molecules either by binding to its putative IGFBP-3R (receptor) to monitor its signal and induce apoptosis or bind to TGF-β receptor resulting in Smad activation which leads to apoptosis. IGFBP- 3 can also activate Stat-1 or bind to RXR-α to induce its anti-proliferative and pro-apoptotic effects
IGF dependent and independent effects of IGFBP-3. IGF-1 can bind to IGF-I receptor and stimulate cell proliferation. IGFBP-3 blocks IGF-I to bind to its receptor resulting in the induction of apoptosis. IGFBP-3 can also induce apoptosis on its own by IGF-I independent mechanism
IGFBP-3 entry into the cell by different pathways. IGFBP-3 in the media seemingly binds with plasma membrane IGFBP-3 receptor to activate signal transduction pathway or enters into the cell by endocytosis to induce apoptosis. IGFBP-3 may either directly activate signal transduction pathway by binding to some receptor to induce apoptosis or in the form of vesicular IGFBP-3 which enters through endoplasmic reticulum membrane into the cytosol and possibly gets translocated into the nucleus
Alternatively, IGFBP-3 may possibly enter into the cell by endocytosis (Figure 3). It has also been reported in some other studies that IGFBP-3 binds to RXRα (Figure 1) and induce its pro-apoptotic effects in PC-3 human prostate cancer cells [30] . Surprisingly, recent studies have shown that IGFBP-3 fail to gain entry or be inter- nalized upon binding to IGF-1 in the extracellular media to induce its pro-apoptotic effects in non-transformed mammary epithelial cells [31] .
3. Pathways Involved in IGFBP-3 Signaling
IGFBP-3 action results in the activation of various signal transduction pathways [32] and Stat-1 (signal transducer and activator of transcription 1) has been known to have a functional role in IGFBP-3-induced apoptosis (Figure 1) in rat chondroprogenitor cells [33] , although our previous studies [34] showed a protective role of Stat-1 on IGFBP-3 induced apoptosis in PC-3 human prostate cancer cells, implying the fact that role of Stat-1 may be cell type dependent.
Some other downstream signaling molecules of IGFBP-3 have also been reported in various other studies [16] [35] [36] . It has been shown from these studies that IGFBP-3 can bind to transforming growth factor-β (TGF-β) cell surface receptors and one of the studies have shown direct interaction of IGFBP-3 with TGF-β-receptor typeV (TGF-β-RV) in mink lung epithelial cells [37] .
IGFBP-3 has also been known to bind and activate intracellular signaling by forming a hetero-meric complex with other TGF-β receptors (TGF-β RII and TGF-β RI) in T47D breast cancer cells [35] [36] . Besides, addition of IGFBP-3 resulted in the activation of Smad 2 phosphorylation and cell growth inhibition in these cells. It has also been shown that IGFBP-3 mediates its pro-apoptotic effects via TGF-β in PC-3 human prostate cancer cells [16] . Results from our previous studies indicated the inhibition of TGF-β signaling in presence of IGFBP-3 in PC-3 human prostate cancer cells [34] , although we did not study the Smad activation in these cells.
It has also been reported that IGFBP-3 down-regulates Akt activity in human epidermal growth factor receptor-2 (HER-2) over expressed MCF-7 breast cancer cells [38] , in this regard recent studies have shown that IGFBP-3 induces apoptosis in MCF-7 breast cancer cells by inhibiting IGF-I/Akt survival pathway [39] . Previous studies also indicated that IGFBP-3 can bind to a new cell death receptor (IGFBP-3R), a single-span membrane protein which specifically binds to IGFBP-3 but doesn’t bind to other IGFBP’s. In vivo studies using prostate and breast cancer xenografts in athymic nude mice, showed anti-tumor effects of IGFBP-3R [40] . It was shown from the in vitro studies that IGFBP-3R triggers IGFBP-3 induced apoptosis in various cancer cells via a caspase-8 dependent pathway. IGFBP-3R directly interacts and activates caspase-8 in inducing apoptosis and knockdown of caspase-8 expression or activity can lead to inhibition of IGFBP-3/IGFBP-3R induced apoptosis. All these studies clearly indicate that IGFBP-3 induces its anti-proliferative and pro-apoptotic effects either by sequestering IGF-1 to prevent it to bind to Insulin-like growth factor-I receptor (IGF-IR) in an IGF dependent manner or by activating several candidate molecules via signal transduction pathway independent of IGF binding. Although insulin-like growth factor binding protein-3 receptor (IGFBP-3R) has been known to be directly involved in IGFBP-3 action and may prove to be an important target molecule for the treatment of cancer, further studies are still needed to clarify the role of this receptor or other IGFBP-3 cell surface binding protein(s) in IGFBP-3 mediated cell signaling events.
4. Conclusion
IGFBP-3 is known to activate various downstream signaling molecules. Some of these signaling events could be initiated after binding to its receptor independent of IGF-I binding, to induce anti-proliferative and pro-apoptotic effects in a certain type of cancer cells. On the other hand, IGFBP-3 can also bind to IGF-1 to modulate its ability to bind to IGF-1 receptor to inhibit cell proliferation and cell survival, resulting in cell death.
Funding
This work was supported by an intramural grant from NIDDK, NIH.
NOTES@endMarkP#wang#_title:ep!!!
*Corresponding author.
ReferencesWOOD W.I., CACHIANES G., HENZEL W.J., WINSLOW G.A., SPENCER S.A., HELLMISS R., MARTIN J.L. , BAXTER R.C. ,et al. (1988)CLONING AND EXPRESSION OF THE GROWTH HORMONE-DEPENDENT INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2, 1176-1185.HTTP://DX.DOI.ORG/10.1210/MEND-2-12-1176MEHTA H.H., GAO Q., GALET C., PAHARKOVA V., WAN J., SAID J., SOHN J.J., LAWSON G., COHEN P., COBB L.J. , LEE K.W. ,et al. (2011)IGFBP-3 IS A METASTASIS SUPPRESSION GENE IN PROSTATE CANCER 71, 5154-5163.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-10-4513CHAN J.M., STAMPFER M.J., GIOVANNUCCI E., GANN P.H., MA J., WILKINSON P., HENNEKENS C.H. , POLLAK M. ,et al. (1998)PLASMA INSULIN-LIKE GROWTH FACTOR-I AND PROSTATE CANCER RISK: A PROSPECTIVE STUDY 279, 563-566.HTTP://DX.DOI.ORG/10.1126/SCIENCE.279.5350.563CHAN J.M., STAMPFER M.J., MA J., GANN P., GAZIANO J.M., POLLAK M. , GIOVANNUCCI E. ,et al. (2002)INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF BINDING PROTEIN-3 AS PREDICTORS OF ADVANCED-STAGE PROSTATE CANCER 94, 1099-1106.HTTP://DX.DOI.ORG/10.1093/JNCI/94.14.1099MA J., POLLAK M.N., GIOVANNUCCI E., CHAN J.M., TAO Y., HENNEKENS C.H. , STAMPFER M.J. ,et al. (1999)PROSPECTIVE STUDY OF COLORECTAL CANCER RISK IN MEN AND PLASMA LEVELS OF INSULIN-LIKE GROWTH FACTOR (IGF)-I AND IGF-BINDING PROTEIN-3 91, 620-625.HTTP://DX.DOI.ORG/10.1093/JNCI/91.7.620GIOVANNUCCI E., POLLAK M.N., PLATZ E.A., WILLETT W.C., STAMPFER M.J., MAJEED N., COLDITZ G.A., SPEIZER F.E. , HANKINSON S.E. ,et al. (2000)GIOVANNUCCI, E., POLLAK, M.N., PLATZ, E.A., WILLETT, W.C., STAMPFER, M.J., MAJEED, N., COLDITZ, G.A., SPEIZER, F.E. AND HANKINSON, S.E. A PROSPECTIVE STUDY OF PLASMA INSULIN-LIKE GROWTH FACTOR-1 AND BINDING PROTEIN-3 AND RISK OF COLORECTAL NEOPLASIA IN WOMEN 9, 345-349.HOCHSCHEID R., JAQUES G. , WEGMANN B. ,et al. (2000)TRANSFECTION OF HUMAN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 3 GENE INHIBITS CELL GROWTH AND TUMORIGENICITY: A CELL CULTURE MODEL FOR LUNG CANCER 166, 553-563.HTTP://DX.DOI.ORG/10.1677/JOE.0.1660553DEVI G.R., SPRENGER C.C., PLYMATE S.R. , ROSENFELD R.G. ,et al. (2002)INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 INDUCES EARLY APOPTOSIS IN MALIGNANT PROSTATE CANCER CELLS AND INHIBITS TUMOR FORMATION IN VIVO 51, 141-152.HTTP://DX.DOI.ORG/10.1002/PROS.10068HANAFUSA T., YUMOTO Y., NOUSO K., NAKATSUKASA H., ONISHI T., FUJIKAWA T., TANIYAMA M., NAKAMURA S., UEMURA M., TAKUMA Y., YUMOTO E., HIGASHI T. , TSUJI T. ,et al. (2002)REDUCED EXPRESSION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 AND ITS PROMOTER HYPERMETHYLATION IN HUMAN HEPATOCELLULAR CARCINOMA 176, 149-158.HTTP://DX.DOI.ORG/10.1016/S0304-3835(01)00736-4CHANG Y.S., KONG G., SUN S., LIU D., EL-NAGGAR A.K., KHURI F.R., HONG W.K. , LEE H.Y. ,et al. (2002)CHANG, Y.S., KONG, G., SUN, S., LIU, D., EL-NAGGAR, A.K., KHURI, F.R., HONG, W.K. AND LEE, H.Y. CLINICAL SIGNIFICANCE OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 EXPRESSION IN STAGE I NON-SMALL CELL LUNG CANCER 8, 3796-3802.LU X.F., JIANG X.G., LU Y.B., BAI J.H. , MAO Z.B. ,et al. (2005)CHARACTERIZATION OF A NOVEL POSITIVE TRANSCRIPTION REGULATORY ELEMENT THAT DIFFERENTIALLY REGULATES THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) GENE IN SENESCENT CELLS 280, 22606-22615.HTTP://DX.DOI.ORG/10.1074/JBC.M412073200MANNHARDT B., WEINZIMER S.A., WAGNER M., FIEDLER M., COHEN P., JANSEN-DURR P. , ZWERSCHKE W. ,et al. (2000)HUMAN PAPILLOMAVIRUS TYPE 16 E7 ONCOPROTEIN BINDS AND INACTIVATES GROWTH-INHIBITORY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 20, 6483-6495.HTTP://DX.DOI.ORG/10.1128/MCB.20.17.6483-6495.2000BHATTACHARYYA N., PECHHOLD K., SHAHJEE H., ZAPPALA G., ELBI C., RAAKA B., WIENCH M., HONG J. , RECHLER M.M. ,et al. (2006)NONSECRETED INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) CAN INDUCE APOPTOSIS IN HUMAN PROSTATE CANCER CELLS BY IGF-INDEPENDENT MECHANISMS WITHOUT BEING CONCENTRATED IN THE NUCLEUS 281, 24588-24601.HTTP://DX.DOI.ORG/10.1074/JBC.M509463200LALOU C., LASSARRE C. , BINOUX M. ,et al. (1996)LALOU, C., LASSARRE, C. AND BINOUX, M. A PROTEOLYTIC FRAGMENT OF INSULIN-LIKE GROWTH FACTOR (IGF) BINDING PROTEIN-3 THAT FAILS TO BIND IGFS INHIBITS THE MITOGENIC EFFECTS OF IGF-I AND INSULIN 137, 3206-3212.SHAHJEE H., BHATTACHARYYA N., ZAPPALA G., WIENCH M., PRAKASH S. , RECHLER M.M. ,et al. (2008)AN N-TERMINAL FRAGMENT OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) INDUCES APOPTOSIS IN HUMAN PROSTATE CANCER CELLS IN AN IGF-INDEPENDENT MANNER 18, 188-197.HTTP://DX.DOI.ORG/10.1016/J.GHIR.2007.08.006RAJAH R., VALENTINIS B. , COHEN P. ,et al. (1997)INSULIN-LIKE GROWTH FACTOR IGF BINDING PROTEIN-3 INDUCES APOPTOSIS AND MEDIATES THE EFFECTS OF TRANSFORMING GROWTH FACTOR-Β1 ON PROGRAMMED CELL DEATH THROUGH A P53- AND IGF-IN- DEPENDENT MECHANISM 272, 12181-12188.HTTP://DX.DOI.ORG/10.1074/JBC.272.18.12181BUTT A.J., FIRTH S.M., KING M.A. , BAXTER R.C. ,et al. (2000)INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 MODULATES EXPRESSION OF BAX AND BCL-2 AND POTENTIATES P53-INDEPENDENT RADIATION-INDUCED APOPTOSIS IN HUMAN BREAST CANCER CELLS 275, 39174-39181.HTTP://DX.DOI.ORG/10.1074/JBC.M908888199HONG J., ZHANG G., DONG F. , RECHLER M.M. ,et al. (2002)INSULIN-LIKE GROWTH FACTOR (IGF)-BINDING PROTEIN-3 MUTANTS THAT DO NOT BIND IGF-I OR IGF-II STIMULATE APOPTOSIS IN HUMAN PROSTATE CANCER CELLS 277, 10489-10497.HTTP://DX.DOI.ORG/10.1074/JBC.M109604200KIM H.S., LEE W.J., LEE S.W., CHAE H.W., KIM D.H. , OH Y. ,et al. (2010)KIM, H.S., LEE, W.J., LEE, S.W., CHAE, H.W., KIM, D.H. AND OH, Y. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 INDUCES G1 CELL CYCLE ARREST WITH INHIBITION OF CYCLIN-DEPENDENT KINASE 2 AND 4 IN MCF-7 HUMAN BREAST CANCER CELLS 42, 165-172.WU C., LIU X.B., WANG Y.Y., TIAN H.N., XIE Y.Y., LI Q.J., ZHANG X.K. , LIU F.M. ,et al. (2013)INSULIN-LIKE FACTOR BINDING PROTEIN-3 PROMOTES THE G1 CELL CYCLE ARREST IN SEVERAL CANCER CELL LINES 512, 127-133.HTTP://DX.DOI.ORG/10.1016/J.GENE.2012.09.080GUCEV Z.S., OH Y., KELLEY K.M. , ROSENFELD R.G. ,et al. (1996)GUCEV, Z.S., OH, Y., KELLEY, K.M. AND ROSENFELD, R.G. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 MEDIATES RETINOIC ACID- AND TRANSFORMING GROWTH FACTOR BETA2-INDUCED GROWTH INHIBITION IN HUMAN BREAST CANCER CELLS 56, 1545-1550.RAJAH R., LEE K.W. , COHEN P. ,et al. (2002)RAJAH, R., LEE, K.W. AND COHEN, P. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 MEDIATES TUMOR NECROSIS FACTOR-ALPHA-INDUCED APOPTOSIS: ROLE OF BCL-2 PHOSPHORYLATION 13, 163-171.VASYLYEVA T.L., CHEN X. , FERRY JR. R.J. ,et al. (2005)INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 MEDIATES CYTOKINE-INDUCED MESANGIAL CELL APOPTOSIS 15, 207-214.HTTP://DX.DOI.ORG/10.1016/J.GHIR.2005.02.008RYAN K.M. , VOUSDEN K.H. ,et al. (1998)RYAN, K.M. AND VOUSDEN, K.H. CHARACTERIZATION OF STRUCTURAL P53 MUTANTS WHICH SHOW SELECTIVE DEFECTS IN APOPTOSIS BUT NOT CELL CYCLE ARREST 18, 3692-3698.GRIMBERG A., LIU B., BANNERMAN P., EL-DEIRY W.S. , COHEN P. ,et al. (2002)GRIMBERG, A., LIU, B., BANNERMAN, P., EL-DEIRY, W.S. AND COHEN, P. IGFBP-3 MEDIATES P53-INDUCED APOPTOSIS DURING SERUM STARVATION 21, 327-335.HARMS K.L. , CHEN X. ,et al. (2005)THE C TERMINUS OF P53 FAMILY PROTEINS IS A CELL FATE DETERMINANT 25, 2014-2030.HTTP://DX.DOI.ORG/10.1128/MCB.25.5.2014-2030.2005RECHLER M.M. , CLEMMONS D.R. ,et al. (1998)REGULATORY ACTIONS OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS 9, 176-183.HTTP://DX.DOI.ORG/10.1016/S1043-2760(98)00047-2FIRTH S.M. , BAXTER R.C. ,et al. (2002)CELLULAR ACTIONS OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS 23, 824-854.HTTP://DX.DOI.ORG/10.1210/ER.2001-0033HAN J., JOGIE-BRAHMIN S., HARADA A. , OH Y. ,et al. (2011)INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 SUPPRESSES TUMOR GROWTH VIA ACTIVATION OF CASPASE-DEPENDENT APOPTOSIS AND CROSS-TALK WITH NF-ΚB SIGNALING 307, 200-210.HTTP://DX.DOI.ORG/10.1016/J.CANLET.2011.04.004ZAPPALA G., ELBI C., EDWARDS J., GORENSTEIN J., RECHLER M.M. , BHATTACHARYYA N. ,et al. (2008)INDUCTION OF APOPTOSIS IN HUMAN PROSTATE CANCER CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 DOES NOT REQUIRE BINDING TO RETINOID X RECEPTOR-Α 149, 1802-1812.HTTP://DX.DOI.ORG/10.1210/EN.2007-1315LEIBOWITZ B.J., AGOSTINI-DREYER A., JETZT A.E., KRUMM C.S. , COHICK W.S. ,et al. (2013)IGF BINDING PROTEIN-3 MEDIATES STRESS-INDUCED APOPTOSIS IN NON-TRANSFORMED MAMMARY EPITHELIAL CELLS 228, 734-742.HTTP://DX.DOI.ORG/10.1002/JCP.24220RICORT J.M. ,et al. (2004)INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN (IGFBP) SIGNALLING 14, 277-286.HTTP://DX.DOI.ORG/10.1016/J.GHIR.2004.02.002SPAGNOLI A., TORELLO M., NAGALLA S.R., HORTON W.A., PATTEE P., CHIARELLI F., ROBERTS JR. C.T. , ROSENFELD R.G. ,et al. (2002)IDENTIFICATION OF STAT-1 AS A MOLECULAR TARGET OF IGFBP-3 IN THE PROCESS OF CHONDROGENESIS 277, 18860-18867.HTTP://DX.DOI.ORG/10.1074/JBC.M200218200SHAHJEE H.M., KEFAS B., BHATTACHARYYA N. , RADWAN M.K. ,et al. (2013)SIGNAL TRANSDUCTION PATHWAYS MEDIATED BY SECRETED AND NON-SECRETED FORMS OF INTACT INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 AND ITS 1-97 N-TERMINAL FRAGMENT IN PC-3 HUMAN PROSTATE CANCER CELLS 4, 1290-1297.HTTP://DX.DOI.ORG/10.4236/JCT.2013.48152FANAYAN S., FIRTH S.M., BUTT A.J. , BAXTER R.C. ,et al. (2000)GROWTH INHIBITION BY INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 IN T47D BREAST CANCER CELLS REQUIRES TRANSFORMING GROWTH FACTOR-Β (TGF-Β) AND THE TYPE II TGF-Β RECEPTOR 275, 39146-39151.HTTP://DX.DOI.ORG/10.1074/JBC.M006964200FANAYAN S., FIRTH S.M. , BAXTER R.C. ,et al. (2002)SIGNALLING THROUGH THE SMAD PATHWAY BY INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 IN BREAST CANCER CELLS. RELATIONSHIP TO TRANSFORMING GROWTH FACTOR-Β1 SIGNALING 277, 7255-7261.HTTP://DX.DOI.ORG/10.1074/JBC.M108038200LEAL S.M., HUANG S.S. , HUANG J.S. ,et al. (1999)INTERACTIONS OF HIGH AFFINITY INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS WITH THE TYPE V TRANSFORMING GROWTH FACTOR-Β RECEPTOR IN MINK LUNG EPITHELIAL CELLS 274, 6711-6717.HTTP://DX.DOI.ORG/10.1074/JBC.274.10.6711JEROME L., ALAMI N., BELANGER S., PAGE V., YU Q., PATERSON J., SHIRY L., PEGRAM M. , LEYL-JONES, B. ,et al. (2006)RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 INHIBITS GROWTH OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 OVEREXPRESSING BREAST TUMORS AND POTENTIATES HERCEPTIN ACTIVITY IN VIVO 66, 7245-7252.HTTP://DX.DOI.ORG/10.1158/0008-5472.CAN-05-3555BROSSEAU, C., PIRIANOV, G. AND COLSTON, K.W. (2013) ROLE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 IN 1,25-DIHYDROXYVITAMIN-D3-INDUCED BREAST CANCER CELL APOPTOSIS. INTERNATIONAL JOURNAL OF CELL BIOLOGY, 2013, ARTICLE ID: 960378. HTTP://DX.DOI.ORG/10.1155/2013/960378INGERMANN A.R., YANG Y.F., HAN J., MIKAMI A., GARZA A.E., MOHANRAJ L., FAN L., IDOWU M., WARE J.L., KIM H.S., LEE D.Y. , OH Y. ,et al. (2010)IDENTIFICATION OF A NOVEL CELL DEATH RECEPTOR MEDIATING IGFBP-3-INDUCED ANTI-TUMOR EFFECTS IN BREAST AND PROSTATE CANCER 285, 30233-30246.HTTP://DX.DOI.ORG/10.1074/JBC.M110.122226